Lead Product(s): Recombinant Alkaline Phosphatase
Therapeutic Area: Nephrology
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Cowen Healthcare Investments
Deal Size: $52.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 31, 2020
New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).